A health economic model to assess the cost-effectiveness of pegylated interferon alpha-2a and ribavirin in patients with moderate chronic hepatitis C and persistently normal alanine aminotransferase levels. [electronic resource]
Producer: 20071011Description: 177-87 p. digitalISSN:- 1784-3227
- Adult
- Aged
- Aged, 80 and over
- Alanine Transaminase -- blood
- Antiviral Agents -- administration & dosage
- Biomarkers -- blood
- Cost-Benefit Analysis
- Dose-Response Relationship, Drug
- Drug Carriers
- Drug Costs
- Drug Therapy, Combination
- Female
- Follow-Up Studies
- Genotype
- Hepacivirus -- genetics
- Hepatitis C, Chronic -- drug therapy
- Humans
- Interferon alpha-2
- Interferon-alpha -- administration & dosage
- Male
- Middle Aged
- Models, Economic
- Polyethylene Glycols -- administration & dosage
- RNA, Viral -- drug effects
- Recombinant Proteins
- Ribavirin -- administration & dosage
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.